Table II.
Tumor response according to RECIST 1.1.
| Variable | AS group (n=49) | GS group (n=52) | P-value |
|---|---|---|---|
| Objective response | 0.001 | ||
| No. of patients | 22 | 8 | |
| % of patients (95% CI)a | 44.90 (30.67–59.77) | 15.38 (6.88–28.08) | |
| Best overall response, n (%) | 0.005 | ||
| Complete response | 0 (0.00) | 0 (0.00) | |
| Partial response | 22 (44.90) | 8 (15.38) | |
| Stable disease | 20 (40.82) | 35 (67.31) | |
| Progressive disease | 5 (10.20) | 8 (15.38) | |
| Not evaluated | 2 (4.08) | 1 (1.92) |
a
Difference in % vs. GS (95% CI) is 29.52 (12.48–46.55). RECIST, response evaluation criteria in solid tumors version; AS, nab-paclitaxel plus S-1; GS, gemcitabine plus S-1; CI, confidence interval.